Omicron-specific boosters near rollout as CDC advisory group signs off

Published September 1, 2022 12:00am ET



<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1662039651694,"cms.content.publishUser":{"_ref":"0000017d-fe9d-da96-ad7d-ffbf8a5c0000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1662039651694,"cms.content.updateUser":{"_ref":"0000017d-fe9d-da96-ad7d-ffbf8a5c0000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"

var _bp = _bp||[]; _bp.push({ "div": "Brid_61970409", "obj": {"id":"27789","width":"16","height":"9","video":"1087729"} }); ","_id":"00000182-f948-d446-af92-fdd969b10000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video EmbedModerna and Pfizer-BioNTech’s updated COVID-19 booster vaccines that target the highly transmittable omicron variant are expected to be ready for administration in a matter of days after an advisory group for the Centers for Disease Control and Prevention signed off on the updated shots.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.